---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-222818"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2026-05-14T11:36:49+00:00"
generated_at: "2026-05-14T11:40:32.198784+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q1 2026 net loss $23.3M; MICVO data on track for mid-2026

## Summary
- Net loss $23.3M ($0.37/share) vs $21.2M ($0.35/share) YoY; R&D expenses rose to $20.0M from $17.0M.
- Cash and equivalents $42.5M; expected runway into Q4 2026.
- MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC (dose cap patients) on track for mid-2026.
- MICVO + pembrolizumab Phase 1/2 combination dose escalation data in 1L R/M HNSCC expected 2H 2026.
- Appointed Nelson Azoulay as Chief Business Officer.

## SEC filing metadata
- accession: 0001193125-26-222818
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2026-05-14T11:36:49+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312526222818/0001193125-26-222818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312526222818/pyxs-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-222818
- JSON: https://secwatch.observer/filing/0001193125-26-222818.json
- Plain text: https://secwatch.observer/filing/0001193125-26-222818.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.